This company has been marked as potentially delisted and may not be actively trading. TradeUP Acquisition (UPTD) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock UPTD vs. OMGA, AIM, SLXN, ALBT, NKGN, BCLI, FRTX, KLTO, APTO, and CELZShould you be buying TradeUP Acquisition stock or one of its competitors? The main competitors of TradeUP Acquisition include Omega Therapeutics (OMGA), AIM ImmunoTech (AIM), Silexion Therapeutics (SLXN), Avalon GloboCare (ALBT), NKGen Biotech (NKGN), Brainstorm Cell Therapeutics (BCLI), Fresh Tracks Therapeutics (FRTX), Klotho Neurosciences (KLTO), Aptose Biosciences (APTO), and Creative Medical Technology (CELZ). These companies are all part of the "biological products, except diagnostic" industry. TradeUP Acquisition vs. Omega Therapeutics AIM ImmunoTech Silexion Therapeutics Avalon GloboCare NKGen Biotech Brainstorm Cell Therapeutics Fresh Tracks Therapeutics Klotho Neurosciences Aptose Biosciences Creative Medical Technology Omega Therapeutics (NASDAQ:OMGA) and TradeUP Acquisition (NASDAQ:UPTD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, community ranking, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability. Which has preferable earnings & valuation, OMGA or UPTD? TradeUP Acquisition has lower revenue, but higher earnings than Omega Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOmega Therapeutics$8.10M0.85-$97.43M-$1.33-0.09TradeUP AcquisitionN/AN/A-$1MN/AN/A Is OMGA or UPTD more profitable? TradeUP Acquisition has a net margin of 0.00% compared to Omega Therapeutics' net margin of -902.93%. TradeUP Acquisition's return on equity of 0.00% beat Omega Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Omega Therapeutics-902.93% -213.13% -41.24% TradeUP Acquisition N/A N/A -3.38% Which has more volatility and risk, OMGA or UPTD? Omega Therapeutics has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500. Comparatively, TradeUP Acquisition has a beta of 0.12, indicating that its share price is 88% less volatile than the S&P 500. Does the MarketBeat Community favor OMGA or UPTD? Omega Therapeutics received 28 more outperform votes than TradeUP Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformOmega TherapeuticsOutperform Votes2873.68% Underperform Votes1026.32% TradeUP AcquisitionN/AN/A Does the media refer more to OMGA or UPTD? In the previous week, TradeUP Acquisition's average media sentiment score of 0.67 beat Omega Therapeutics' score of 0.00 indicating that TradeUP Acquisition is being referred to more favorably in the news media. Company Overall Sentiment Omega Therapeutics Neutral TradeUP Acquisition Positive Do analysts prefer OMGA or UPTD? Omega Therapeutics currently has a consensus price target of $9.20, suggesting a potential upside of 7,260.00%. Given Omega Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Omega Therapeutics is more favorable than TradeUP Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Omega Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80TradeUP Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals hold more shares of OMGA or UPTD? 97.5% of Omega Therapeutics shares are owned by institutional investors. Comparatively, 35.0% of TradeUP Acquisition shares are owned by institutional investors. 8.5% of Omega Therapeutics shares are owned by company insiders. Comparatively, 55.1% of TradeUP Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryOmega Therapeutics beats TradeUP Acquisition on 7 of the 13 factors compared between the two stocks. Get TradeUP Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for UPTD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UPTD vs. The Competition Export to ExcelMetricTradeUP AcquisitionBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.17M$2.92B$5.47B$7.82BDividend YieldN/A1.91%5.43%4.30%P/E RatioN/A29.7522.3718.43Price / SalesN/A481.28391.12101.46Price / CashN/A168.6838.1834.62Price / Book-0.633.036.684.19Net Income-$1M-$72.17M$3.22B$248.05M TradeUP Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UPTDTradeUP AcquisitionN/A$1.00+4.2%N/A-7.7%$2.17MN/A0.002,021Gap UpOMGAOmega Therapeutics1.8813 of 5 stars$0.13-21.8%$9.20+7,260.0%-94.7%$6.92M$8.10M-0.09120Gap UpAIMAIM ImmunoTech1.9339 of 5 stars$0.09-22.3%$2.75+2,908.8%-77.5%$6.61M$170,000.00-0.1920Gap DownHigh Trading VolumeSLXNSilexion TherapeuticsN/A$0.75-2.7%$5.00+566.7%N/A$6.52MN/A0.00N/ANews CoveragePositive NewsALBTAvalon GloboCare1.2699 of 5 stars$3.57-8.5%N/A-10.2%$5.90M$1.31M-0.185Short Interest ↑NKGNNKGen BiotechN/A$0.13+1.2%N/A-93.2%$5.73M$80,000.00-0.03N/AGap UpBCLIBrainstorm Cell Therapeutics3.6229 of 5 stars$0.88+10.2%$30.00+3,324.7%-87.8%$5.71MN/A-0.1840Short Interest ↑FRTXFresh Tracks TherapeuticsN/A$0.94-0.5%N/A+1.6%$5.59M$10.06M-0.6620KLTOKlotho NeurosciencesN/A$0.17+1.7%N/AN/A$4.76MN/A0.00N/AGap UpAPTOAptose Biosciences1.6679 of 5 starsN/A$93.00+∞N/A$3.66MN/A-0.5831Gap DownHigh Trading VolumeCELZCreative Medical Technology1.2361 of 5 stars$1.97-0.5%N/A-55.4%$3.44M$11,000.00-0.525 Related Companies and Tools Related Companies Omega Therapeutics Alternatives AIM ImmunoTech Alternatives Silexion Therapeutics Alternatives Avalon GloboCare Alternatives NKGen Biotech Alternatives Brainstorm Cell Therapeutics Alternatives Fresh Tracks Therapeutics Alternatives Klotho Neurosciences Alternatives Aptose Biosciences Alternatives Creative Medical Technology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UPTD) was last updated on 4/26/2025 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TradeUP Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share TradeUP Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy UPTD Stock Free UPTD Stock Alerts